Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
PLoS One ; 16(11): e0259823, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-34748615

RESUMO

BACKGROUND: Pediatric SARS-CoV-2 data remain limited and seropositivity rates in children were reported as <1% early in the pandemic. Seroepidemiologic evaluation of SARS-CoV-2 in children in a major metropolitan region of the US was performed. METHODS: Children and adolescents ≤19 years were enrolled in a cross-sectional, observational study of SARS-CoV-2 seroprevalence from July-October 2020 in Northern Virginia, US. Demographic, health, and COVID-19 exposure information was collected, and blood analyzed for SARS-CoV-2 spike protein total antibody. Risk factors associated with SARS-CoV-2 seropositivity were analyzed. Orthogonal antibody testing was performed, and samples were evaluated for responses to different antigens. RESULTS: In 1038 children, the anti-SARS-CoV-2 total antibody positivity rate was 8.5%. After multivariate logistic regression, significant risk factors included Hispanic ethnicity, public or absent insurance, a history of COVID-19 symptoms, exposure to person with COVID-19, a household member positive for SARS-CoV-2 and multi-family or apartment dwelling without a private entrance. 66% of seropositive children had no symptoms of COVID-19. Secondary analysis included orthogonal antibody testing with assays for 1) a receptor binding domain specific antigen and 2) a nucleocapsid specific antigen had concordance rates of 80.5% and 79.3% respectively. CONCLUSIONS: A much higher burden of SARS-CoV-2 infection, as determined by seropositivity, was found in children than previously reported; this was also higher compared to adults in the same region at a similar time. Contrary to prior reports, we determined children shoulder a significant burden of COVID-19 infection. The role of children's disease transmission must be considered in COVID-19 mitigation strategies including vaccination.


Assuntos
COVID-19/sangue , COVID-19/epidemiologia , SARS-CoV-2 , Adolescente , Anticorpos Antivirais/sangue , Antígenos Virais , COVID-19/imunologia , Teste Sorológico para COVID-19 , Criança , Pré-Escolar , Estudos Transversais , Feminino , Humanos , Lactente , Recém-Nascido , Masculino , Análise Multivariada , Pandemias , Fatores de Risco , Estudos Soroepidemiológicos , Estados Unidos
2.
Cardiol Young ; 31(7): 1202-1204, 2021 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-33745461

RESUMO

SARS-CoV-2, which causes the disease COVID-19, generally has a mild disease course in children. However, a severe post-infectious inflammatory process known as multisystem inflammatory syndrome in children has been observed in association with COVID-19. This inflammatory process is a result of an abnormal immune response with similar clinical features to Kawasaki disease. It is well established that multisystem inflammatory syndrome in children is associated with myocardial dysfunction, coronary artery dilation or aneurysms, and occasionally arrhythmias. The most common electrocardiographic abnormalities seen include premature atrial or ventricular ectopy, variable degrees of atrioventricular block, and QTc prolongation, and rarely, haemodynamically significant arrhythmias necessitating extracorporeal membrane oxygenation support. However, presentation with fever, hypotension, and relative bradycardia with a left axis idioventricular rhythm has not been previously reported. We present a case of a young adolescent with multisystem inflammatory syndrome in children with myocarditis and a profoundly inappropriate sinus node response to shock with complete resolution following intravenous immunoglobulin.


Assuntos
COVID-19 , Síndrome de Linfonodos Mucocutâneos , Adolescente , Criança , Humanos , Síndrome de Linfonodos Mucocutâneos/complicações , Síndrome de Linfonodos Mucocutâneos/diagnóstico , Síndrome de Linfonodos Mucocutâneos/tratamento farmacológico , SARS-CoV-2 , Síndrome do Nó Sinusal , Síndrome de Resposta Inflamatória Sistêmica
4.
Pediatr Infect Dis J ; 28(6): 545-7, 2009 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-19483524

RESUMO

Human parechovirus-3 (HPeV-3) is an emerging pathogen that has been described as a cause of neonatal sepsis. Human parechoviruses are a family of viruses closely related to enteroviruses; however, enteroviral PCR will not detect HPeVs. We present clinical details of neonatal meningoencephalitis and hepatitis-coagulopathy syndrome caused by HPeV-3 infection.


Assuntos
Meningoencefalite/diagnóstico , Parechovirus/isolamento & purificação , Infecções por Picornaviridae/diagnóstico , Sepse/diagnóstico , Aciclovir/uso terapêutico , Antivirais/uso terapêutico , Líquido Cefalorraquidiano/virologia , Humanos , Recém-Nascido , Masculino , Meningoencefalite/tratamento farmacológico , Meningoencefalite/virologia , Parechovirus/genética , Parechovirus/patogenicidade , Infecções por Picornaviridae/tratamento farmacológico , Infecções por Picornaviridae/virologia , Reação em Cadeia da Polimerase , Sepse/tratamento farmacológico , Sepse/virologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA